We are live on ! Find out more
ASMB icon

Assembly Biosciences

105 hedge funds and large institutions have $640M invested in Assembly Biosciences in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

199% more call options, than puts

Call options by funds: $12.7M | Put options by funds: $4.24M

53% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 30

0.13% more ownership

Funds ownership: 6.61%6.74% (+0.13%)

6% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 18

2% less funds holding

Funds holding: 107105 (-2)

19% less capital invested

Capital invested by funds: $789M → $640M (-$149M)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

Holders
105
Holders Change
-2
Holders Change %
-1.87%
% of All Funds
2.4%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
17
Increased
46
Reduced
30
Closed
18
Calls
$12.7M
Puts
$4.24M
Net Calls
+$8.44M
Net Calls Change
-$3.1M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
1
EcoR1 Capital
California
$115M
Jennison Associates
2
Jennison Associates
New York
$96.9M +$1.6M +3,031 +1%
BlackRock
3
BlackRock
New York
$48.6M +$7.19M +13,604 +15%
ACP
4
Acuta Capital Partners
California
$45.6M +$2.07M +3,916 +4%
ACA
5
Avoro Capital Advisors
New York
$37.8M -$5.75M -10,875 -12%
Vanguard Group
6
Vanguard Group
Pennsylvania
$31.9M +$893K +1,688 +3%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$31.6M +$10.7M +20,299 +43%
O
8
OrbiMed
New York
$28.3M
RSCM
9
Rock Springs Capital Management
Maryland
$17.6M +$308K +583 +2%
State Street
10
State Street
Massachusetts
$14.3M +$3.24M +6,131 +25%
Invesco
11
Invesco
Georgia
$10.4M -$3.04M -5,751 -21%
Northern Trust
12
Northern Trust
Illinois
$9.46M +$801K +1,514 +8%
GTC
13
Ghost Tree Capital
New York
$9.21M +$3.75M +7,083 +57%
EA
14
Emerald Advisers
Pennsylvania
$9.15M +$4.65M +8,796 +83%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$8.23M +$1.34M +2,535 +17%
EMFAT
16
Emerald Mutual Fund Advisers Trust
Pennsylvania
$7.96M +$4.07M +7,696 +83%
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$7.84M +$1.1M +2,084 +14%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$6.54M -$116K -220 -2%
PA
19
Perceptive Advisors
New York
$5.91M -$14.4M -27,161 -68%
LSC
20
Lyon Street Capital
California
$5.89M +$503K +952 +8%
BBA
21
Baker Bros. Advisors
New York
$5.83M -$1.99M -3,767 -23%
Axa
22
Axa
France
$5.46M +$984K +1,860 +19%
Victory Capital Management
23
Victory Capital Management
Texas
$4.55M -$292K -553 -5%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$4.5M +$1.98M +3,752 +64%
Renaissance Technologies
25
Renaissance Technologies
New York
$4.5M -$2.3M -4,350 -31%

ASMB Hedge Fund Activity: Q2 2018 in Review

105 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2018, worth a combined $640M — down 19% from $789M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ASMB and 17 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 46 added.

The largest buyer was Janus Henderson Group, adding an estimated $10.7M. The largest seller was Perceptive Advisors, cutting an estimated $14.4M.

  • 105 institutional investors held Assembly Biosciences (ASMB) as of Q2 2018, down from 107 in Q1 2018.
  • Funds reported $640M of Assembly Biosciences stock for Q2 2018, down 19% quarter-over-quarter.
  • 17 funds opened new Assembly Biosciences positions in Q2 2018 and 18 closed out, a net change of -1 holder.
  • The largest Assembly Biosciences buyer in Q2 2018 was Janus Henderson Group, an estimated $10.7M added.
  • The largest Assembly Biosciences seller in Q2 2018 was Perceptive Advisors, an estimated $14.4M sold.

Based on aggregated 13F filings for Q2 2018.